Physician profile
Fares Khater
NPI 1992732101
$411,628.33
in general payments reported to CMS, 2019-2025
17 companies · $91K in 2025
The $91K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $35K · 2021: $27K · 2022: $42K · 2023: $83K · 2024: $87K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196K · Travel and Lodging: $28K · Consulting Fee: $17K · Honoraria: $11K · Food and Beverage: $9,299 · Education: $42.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $195,719.00 |
| Travel and Lodging | $27,952.47 |
| Consulting Fee | $16,570.00 |
| Honoraria | $10,585.00 |
| Food and Beverage | $9,299.11 |
| Education | $42.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $185,269.72 | 2019-2025 | Epclusa, Veklury, Biktarvy |
| Abbvie INC. | $117,216.86 | 2019-2025 | |
| Melinta Therapeutics, LLC | $36,794.84 | 2022-2025 | Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $33,352.95 | 2022-2024 | Nuzyra |
| La Jolla Pharmaceutical Company | $26,592.73 | 2022-2025 | Xacduro, Zevtera, Xerava |
| Allergan, INC. | $10,833.98 | 2019-2021 | |
| Orasure Technologies INC. | $1,000.00 | 2025 | Inteliswab |
| Shionogi INC | $125.00 | 2023 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.41 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $94.28 | 2023-2024 | Rybelsus, Ozempic |
| Grifols USA, LLC | $78.85 | 2021-2023 | Prolastin-C Liquid, Xembify |
| Otsuka America Pharmaceutical, INC. | $38.07 | 2023 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $37.26 | 2025 | Zerbaxa |
| Exact Sciences Corporation | $35.59 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $16.72 | 2023 | Mounjaro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.55 | 2023 | |
| Insmed, INC. | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fares Khater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.